Seegene Stock Current Valuation
| 096530 Stock | KRW 23,050 250.00 1.10% |
Valuation analysis of Seegene helps investors to measure Seegene's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Seegene's price fluctuation is very steady at this time. Calculation of the real value of Seegene is based on 3 months time horizon. Increasing Seegene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Seegene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Seegene Stock. However, Seegene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23050.0 | Real 21227.28 | Hype 23050.0 | Naive 22574.84 |
The real value of Seegene Stock, also known as its intrinsic value, is the underlying worth of Seegene Company, which is reflected in its stock price. It is based on Seegene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Seegene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Seegene helps investors to forecast how Seegene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Seegene more accurately as focusing exclusively on Seegene's fundamentals will not take into account other important factors: Seegene Company Current Valuation Analysis
Seegene's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Seegene Current Valuation | 3.51 T |
Most of Seegene's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seegene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Seegene has a Current Valuation of 3.51 T. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
Seegene is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 4.5 Trillion. Seegene totals roughly 3.51 Trillion in current valuation claiming about 78% of equities under Health Care industry.Seegene Fundamentals
| Return On Equity | 0.32 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 3.51 T | |||
| Shares Outstanding | 25.99 M | |||
| Shares Owned By Insiders | 30.90 % | |||
| Shares Owned By Institutions | 9.23 % | |||
| Price To Earning | 140.12 X | |||
| Price To Sales | 0.65 X | |||
| Revenue | 1.37 T | |||
| Gross Profit | 1 T | |||
| EBITDA | 415.89 B | |||
| Net Income | 536.56 B | |||
| Cash And Equivalents | 432.13 B | |||
| Total Debt | 102.81 B | |||
| Debt To Equity | 8.90 % | |||
| Current Ratio | 4.91 X | |||
| Cash Flow From Operations | 334.02 B | |||
| Target Price | 52050.0 | |||
| Number Of Employees | 1.01 K | |||
| Beta | -0.97 | |||
| Market Capitalization | 700.48 B | |||
| Total Asset | 1.49 T | |||
| Retained Earnings | 46.11 B | |||
| Working Capital | 139.97 B | |||
| Current Asset | 151.8 B | |||
| Current Liabilities | 11.83 B | |||
| Z Score | 3.6 | |||
| Annual Yield | 0 % | |||
| Net Asset | 1.49 T |
About Seegene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seegene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seegene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seegene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Seegene Stock
Seegene financial ratios help investors to determine whether Seegene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seegene with respect to the benefits of owning Seegene security.